EP0248838A1 - Compositions for combatting diarrhoea - Google Patents

Compositions for combatting diarrhoea

Info

Publication number
EP0248838A1
EP0248838A1 EP19860906963 EP86906963A EP0248838A1 EP 0248838 A1 EP0248838 A1 EP 0248838A1 EP 19860906963 EP19860906963 EP 19860906963 EP 86906963 A EP86906963 A EP 86906963A EP 0248838 A1 EP0248838 A1 EP 0248838A1
Authority
EP
European Patent Office
Prior art keywords
substances
composition according
adhesine
diarrhoea
combatting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860906963
Other languages
German (de)
French (fr)
Inventor
Frits Karel De Graaf
Antonius Arnoldus Christiaan Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Original Assignee
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging voor Christelijk Wetenschappelijk Onderwijs
Publication of EP0248838A1 publication Critical patent/EP0248838A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Definitions

  • compositions for combatting diarrhoea Compositions for combatting diarrhoea
  • V. cholearae ⁇ .coli appears to be the main procreator. No reliable figures are known with respect to slaughter cattle but the loss will certainly run into a year.
  • Enterotoxic E.coii stems distinguish themselves from commensal non-patho ⁇ eneous stems in that they comprise two important virulence factors, to wit: the production of enterotoxins and the presence of adhesion antigens.
  • the adhesion antigens of ⁇ .coli consist of electron microscopically visible thread-like appendixes on the bacterium surface indicated as fi briae or pili. Said fimbriae appear to be consisting of hundreds of identical protein sub-units having a molecular weight in the order of magnitude of 25,000. Through the fimbriae the bacterium appears to be capable of colonizing .the intestinalepitheliumand of proliferating the intestine in this way. As soon as the colonisation is effected the produced and excreted enterotoxin causes the development of diarrhoea.
  • K88 One of the adhesion antigens in enterotoxic E.coli- stems from piglets is indicated as K88.
  • Three variants of the K88 adhesine are known which can properly be immunologically distinguished.
  • the primary structure of the subunit,of which the adhesine is composed, of each of said variants has been completely elucidated by us.
  • conserved areas identical amino acid sequences in the subunit variants
  • variable amino acid sequences appear to be present on certain sites in which the three variants distinguish themselves from - . -
  • each variant fragment can be isolated which can block the binding of the adhesine carrying bacteria to erythrocytes (haemagglutination reaction) or to intestinal epithelial cells in low concentrations. Said fragments originate from the conserved parts of the subunit variants. Analysis of three isolated fragments showed that there is question here of the following tripeptides: serine-leucine-phenylalanine, isoleucine-alanine-phenylalanine and alanine-isoleucine- phenylalanine. Said peptides are resistant to decomposition by proteolytic enzymes from the gastro-intestinai tract.
  • amino acid sequences are present on certain sites which show a strong affinity for the adhesine receptors. Said amino acid sequences, therefore, possibly form an essential part of the natural receptor binding site.
  • the possibly occurring absorption of said substances by the intestinal epithelium can be prevented by coupling said substances to inert macromolecular carriers.
  • compositions according to the invention can also be used with adults to combat diarrhoea caused by enterotoxic E.coli-stems.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Une composition thérapeutique pour le traitement et la prévention de la diarrhée comprend une ou plusieurs substances qui arrêtent les récepteurs d'adhésine présents sur l'épithélium intestinal. Lesdites substances sont de préférence des peptides, en particulier de Ser-Leu-Phe, de Ile-Ala-Phe et/ou de Ala-Ile-Phe.A therapeutic composition for the treatment and prevention of diarrhea comprises one or more substances which stop the adhesin receptors present on the intestinal epithelium. Said substances are preferably peptides, in particular Ser-Leu-Phe, Ile-Ala-Phe and / or Ala-Ile-Phe.

Description

Compositions for combatting diarrhoea
The most important procreators of neonataldiarrhoea with human beings and animals are the enterotoxical E. coli stems. With babies or very young children and with new-bo cattle this infection almost always has a lethal course. It appears from recent figures from the WHO that each year 500 million babies and young children (in particular in the developing countries) suffer from diarrhoea which causes over 5 million victims.
Besides V. cholearae Ξ.coli appears to be the main procreator. No reliable figures are known with respect to slaughter cattle but the loss will certainly run into milliards a year.
Enterotoxic E.coii stems distinguish themselves from commensal non-pathoσeneous stems in that they comprise two important virulence factors, to wit: the production of enterotoxins and the presence of adhesion antigens. The adhesion antigens of Ξ.coli consist of electron microscopically visible thread-like appendixes on the bacterium surface indicated as fi briae or pili. Said fimbriae appear to be consisting of hundreds of identical protein sub-units having a molecular weight in the order of magnitude of 25,000. Through the fimbriae the bacterium appears to be capable of colonizing .the intestinalepitheliumand of proliferating the intestine in this way. As soon as the colonisation is effected the produced and excreted enterotoxin causes the development of diarrhoea.
Experiments with mutated stems which cannot produce either adhesion antigens or enterotoxin anymore proved that said stems cause no or a very slight, passing form of diarrhoea.
For some time various research teams have been occupied wi the question whether prevention of this type of infections
through induction of protecting antibodies is possible. It appeared that administration of toxoid does raise antitoxin immuno-globulins , but that these antibodies do not or only partly give protection.
A second approach is based on inducing antibodies directed against the adhesion antigens. This approach appeared to be successful. Vaccination with purified adhesine preparations in most cases appears to give a sufficiently high respons of protectinσ antibodies to protect new-born descendants against the infe ion. . All these experiments relate to infections with piglets, calves or lambs. Various companies bring this type of vaccir.s on rhe market.
It is a problem, wit rhe vaccination of slauσhter cattle with purified antigen, preparations that Ξ.coli can produce various different adhesion antigens, so that now it is clear that more and more different adhesion antigens have to be added to the commercial vacci s.
Some stems only produce oneadhesion antigen, others can synthetize 2 or even 3 adhesion antigens simultaneously.
It is a second problem relating to this type of combatting diarrhoea that vaccination of the parent animals (cows, sows) indeed has a preventive effect and protects the descendants, but, in view of the costs that go with it, this usually can only be used in companies in trouble. From a therapeutical point of view vaccination at the moment at which the infection manifests itself is useless, of course.
In regard of the fact that vaccination is usually only used if problems are to be expected diarrhoea is still combatted on a large scalewith antibiotics, which has L many disadvantages (costs, side-effects, etc.). Therefore, other forms of therapeutics are searched for. The approach chosen is directed to the prevention of colonization, i.e. attaching of the bacteria to the intestinal~epithelium.lt appeared to be possible to combatdiarrhoea by oral administration of (monoclonal) antibodies directed against the adhesion antigens on the bacteria surface. A first composition for combatting neonatal diarrhoea with calves is now commercially available (Molecular Genetics) but relatively little is known about its success. Disadvantages are for instance the costs and the tenabilitv of the preparation.
The above mentioned therapeutical approach is directed against the infecting microorganism. Now it has appeared that a novel therapy can be directed to blocking the achnsir.e receptors resen on the intestinal epithelium.
Until recently of none of the adhesines of enterotoxic E.coli-stems it was known which part (or parts) of the structure is (are) of importance for the receptor recognition.
Surprisingly it has appeared now that here it concerns spatially very restricted structures.
One of the adhesion antigens in enterotoxic E.coli- stems from piglets is indicated as K88. Three variants of the K88 adhesine are known which can properly be immunologically distinguished. The primary structure of the subunit,of which the adhesine is composed, of each of said variants has been completely elucidated by us. Besides conserved areas (identical amino acid sequences in the subunit variants) variable amino acid sequences appear to be present on certain sites in which the three variants distinguish themselves from - . -
each other. With digestions of denatured subunits with proteol tic enzymes it has appeared now that of each variant fragments can be isolated which can block the binding of the adhesine carrying bacteria to erythrocytes (haemagglutination reaction) or to intestinal epithelial cells in low concentrations. Said fragments originate from the conserved parts of the subunit variants. Analysis of three isolated fragments showed that there is question here of the following tripeptides: serine-leucine-phenylalanine, isoleucine-alanine-phenylalanine and alanine-isoleucine- phenylalanine. Said peptides are resistant to decomposition by proteolytic enzymes from the gastro-intestinai tract.
All of the three isolated and identified tripeptides have been synthetized. The synthetic peptides have the same effect and activity as the peptides isolated from the adhesine.
Therefore, in the K88 adhesine known amino acid sequences are present on certain sites which show a strong affinity for the adhesine receptors. Said amino acid sequences, therefore, possibly form an essential part of the natural receptor binding site.
Provisional research with respect to the adhesine antigen K99 of enterotoxic E.coli-stems from calves and lambs points out that here spatially very restricted structures are responsible for attaching to the receptor as well.
As the above-mentioned peptides as it were form an imitation of the natural receptor binding site as it occurs on the adhesine at the bacterium surface, said peptides will compete in the intestine with the bacterium for attaching to the intestinal epithelium. Once bound bacteria can also be removed from the intestinal epithelium by the peptides.
With respect to the short duration of the infection (1-2 days) blockade of the intestinal epithelium receptors will only have to last for a short period of time. This limitation of the duration of the blockade is effected by the host himself as intestinal epithelial cells (enterocytes) are replaced and released fast (usually within 24 hours) by new making.
On account of the above invention substances' with the spatially very restricted structures meant will be inserted into food or into therapeutical compositions.
The possibly occurring absorption of said substances by the intestinal epithelium, can be prevented by coupling said substances to inert macromolecular carriers.
The above mentioned spatially very restricted structures such as tripeptides can be isolated or synthetized cheaply and can be preserved very well. They do not have any disadvantageous effect upon the host.
Besides use with new-born descendants the therapeutical compositions according to the invention can also be used with adults to combat diarrhoea caused by enterotoxic E.coli-stems.

Claims

V_ A I :. S
1. Therapeutical composition for combatting and preventin diarrhoea, characterized by the presence of one or more substances which block the adhesine receptors present on the intestinal epithelium.
2. Composition according to claim 1, characterized by the presence of substances which block specifically adhesine receptors.
3. Composition according to claim 1 or 2, characterized by the presence of one or more substances, the molecules of which comprise one or more amino acid units or derivatives.
4. Composition according to claim 3, characterized by the presence of one cr more peptides.
5. Composition according to claim 3 or 4, characterized by the presence of one or more substances having in their molecules at least one amino acid unit belonging to the group consisting of serine, leucine, isoleucine, alanine and phenyl-aianine.
6 . Composition according to claim 5, characterized by the presence of serine-leucine-phenylalanine, isoleucine-alanine-phenvlalanine and/or alanine- isoleucine-phenylalanine.
7. Composition according to one of the preceding claims, characterized in that the adhesine receptors blocking substances are used in combination with an inert macromolecular carrier.
EP19860906963 1985-12-11 1986-12-09 Compositions for combatting diarrhoea Withdrawn EP0248838A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8503413 1985-12-11
NL8503413A NL8503413A (en) 1985-12-11 1985-12-11 PREPARATIONS FOR THE PREVENTION OF DIARRHEE.

Publications (1)

Publication Number Publication Date
EP0248838A1 true EP0248838A1 (en) 1987-12-16

Family

ID=19847002

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860906963 Withdrawn EP0248838A1 (en) 1985-12-11 1986-12-09 Compositions for combatting diarrhoea

Country Status (4)

Country Link
EP (1) EP0248838A1 (en)
JP (1) JPS63501950A (en)
NL (1) NL8503413A (en)
WO (1) WO1987003485A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK53291D0 (en) * 1991-03-25 1991-03-25 Carlbiotech Ltd As SMALL PEPTIDES AND PEPTID RELATED SUBSTANCES AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS
US6818585B2 (en) * 1998-12-30 2004-11-16 Univation Technologies, Llc Catalyst compounds, catalyst systems thereof and their use in a polymerization process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU76538A1 (en) * 1977-01-07 1978-09-18
SU921712A1 (en) * 1979-12-10 1982-04-23 Ереванский политехнический институт им.К.Маркса Machine tool for working crank shaft connecting rod necks
DE3213740A1 (en) * 1982-04-14 1983-12-15 Oerlikon-Boehringer GmbH, 7320 Göppingen Whirl device
JPS591101A (en) * 1982-05-24 1984-01-06 Komatsu Ltd Crankshaft miller

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8703485A1 *

Also Published As

Publication number Publication date
JPS63501950A (en) 1988-08-04
NL8503413A (en) 1987-07-01
WO1987003485A1 (en) 1987-06-18

Similar Documents

Publication Publication Date Title
Pittman The concept of pertussis as a toxin-mediated disease
Svennerholm et al. Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea
DK167879B1 (en) IMMUNOGENT CONJUGATE, PROCEDURE FOR PREPARING THEREOF, AND VACCINE, INCLUDING SUCH CONJUGATE AND CAPSULATED POLYMER FRAGMENT FOR PREPARING CONJUGAT
Frasch et al. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
US5773007A (en) Vaccine compositions
Khoury et al. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine
Deneke et al. Attachment pili from enterotoxigenic Escherichia coli pathogenic for humans
US5919463A (en) Clostridium difficle toxins as mucosal adjuvants
EP3365003A1 (en) Immunogenic fusion protein
AU720567B2 (en) Clostridium difficile toxins as mucosal adjuvants
AU663864B2 (en) Preparation and use of formalin-killed colonization-factor-antigen (CFA)-expressing E. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic E. coli bacteria in humans
CA2257826C (en) Helicobacter pylori adhesin binding group antigen
Miyake et al. Purification and characterization of Vibrio metschnikovii cytolysin
EP0248838A1 (en) Compositions for combatting diarrhoea
JPS58500998A (en) A novel immunogenic composition for preventing diarrhea caused by E. coli, an intestinal toxin generator
Jacob et al. Identification of a 33 kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae El Tor and its role in protection
US6602507B1 (en) Synthetic peptides from streptococcal M protein and vaccines prepared therefrom
CA2303722A1 (en) Campylobacter vaccine
Holmgren et al. Vaccine Development for the Control of Cholera and Related Toxin‐Induced Diarrhoeal Diseases
JPS644492B2 (en)
Bowersock et al. Use of hydrogels to vaccinate calves orally for pneumonic pasteurellosis
Arnon Synthetic peptides as the basis for vaccines against influenza virus and bacterial toxins
Gorringe The effects of growth condition on the expression of virulence determinants of bordetella pertussis
Swanson Partial purification of heat stable enterotoxin produced by Escherichia coli isolated from a case of porcine colibacillosis
Burns Jr Involvement of Fimbriae in attachment by Bordetella Bronchiseptica

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19871214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19890704

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DE GRAAF, FRITS, KAREL

Inventor name: JACOBS, ANTONIUS, ARNOLDUS, CHRISTIAAN